Compare · CDAK vs CGC
CDAK vs CGC
Side-by-side comparison of Codiak BioSciences Inc. (CDAK) and Canopy Growth Corporation (CGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDAK and CGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 22.9x CDAK ($125.2M).
- CGC has hit the wire 6 times in the past 4 weeks while CDAK has been quiet.
- CGC has more recent analyst coverage (19 ratings vs 2 for CDAK).
- Company
- Codiak BioSciences Inc.
- Canopy Growth Corporation
- Price
- $0.06-53.11%
- $1.03-3.27%
- Market cap
- $125.2M
- $2.86B
- 1M return
- -
- -7.59%
- 1Y return
- -
- -20.08%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 2
- 19
Codiak BioSciences Inc.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CDAK
- SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)
- SEC Form 25-NSE filed by Codiak BioSciences Inc.
- SEC Form SC 13G/A filed by Codiak BioSciences Inc. (Amendment)
- Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket
- Stocks That Hit 52-Week Lows On Monday
- SEC Form 4 filed by Howze Yalonda
- SEC Form 4 filed by Sathyanarayanan Sriram
- SEC Form 4 filed by Konstantinov Konstantin
- SEC Form 4 filed by Bain Linda
Latest CGC
- SEC Form SD filed by Canopy Growth Corporation
- Canopy Growth Relaunches Tweed Brand in Germany with New MTL Cannabis Strain Lineup, Marking First International Release following Acquisition
- Canopy Growth Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Canopy Growth Corporation filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD Disclosure, Financial Statements and Exhibits
- Canopy Growth Provides Update on Financial Reporting and Announces Fourth Quarter and Fiscal Year 2026 Financial Results to be Presented on June 15, 2026
- Europe's Cannabis Boom Is Accelerating as Billions Flow into Licensed Markets
- Canopy Growth and Spectrum Therapeutics Expand Medical Portfolio with New 30 and 90-Pack Softgels and Enhanced Dosing Options
- 'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign
- SEC Form 4 filed by Yanofsky Theresa
- SEC Form 4 filed by Atkins M Shan